The reports by Schmelz et al. and Zhang et al. [12, 29], in the incidental treatment of autoimmune diseases in patients with B cell malignancy who received a CAR-T (against CD19 and compound CD19/BCMA, respectively), were the first experiences reported in human autoimmunity. This evidence concerns the gene CD19 and autoimmune disease.